IPAG

Research use only, not for human use.

IPAG is a potent σ-receptor antagonist (pKi=4.3). IPAG can induce cell apoptosis.

IPAG is a potent sigma-1 receptor antagonist with a pKi of 4.3. IPAG induces apoptosis.

Sigma1 inhibition by IPAG causes the autolysosomal degradation of PD-L1 in PC3 (hormone-insensitive prostate cancer) and MDA-MB-231 (triple-negative breast cancer) cell lines and reduces the levels of functional PD-L1 on the surface of the cells.IPAG treatment produces a mean of 100±8 μg per 106 cells. IPAG can inhibit cell proliferation. Treatment with IPAG decreases cell mass.IPAG treatment suppresses phosphorylation of translational regulator proteins p70S6K, S6, and 4E-BP1.Cell Viability Assay Cell Line:T47D cells Concentration:10 μM Incubation Time:24 hours Result:The mean forward scatter height (FSC-H) of DMSO (control) measured 412±5, whereas the mean FSC-H of IPAG treated cells was 390±4. Western Blot Analysis Cell Line:T47D cells Concentration:10 μM Incubation Time: Result:Decreased levels of phospho-threonine 389-p70S6Kinase (P-S6K), phospho-serine 235/236-ribosomal S6 (P-S6), and phospho-serine 65-4E-BP1 (P-4E-BP1).

——

——

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

——

——

193527-91-2

395.28

C17H22IN3

>98% (HPLC)

In Vitro:?DMSO : 8.33 mg/mL (21.07 mM; ultrasonic and adjust pH to 3 with 1M HCl and heat to 60°C )

Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1

——

(-20℃)

With Ice Pack

≥ 2 years